Uqora Maximum Uti Pain Relief Tablet
Product Images NDC 73712-114

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Uqora Maximum Uti Pain Relief (NDC 73712-114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bonafide Health, Llc Dba Uqora, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Carton 12 Ct)

Uqora Maximum UTI Pain Relief tablets contain 99.5 mg Phenazopyridine Hydrochloride per tablet in oral dosage form. The carton highlights fast-targeted relief for urinary pain, burning, urgency, and discomfort, with a two-day supply of 12 tablets. The labeler is Bonafide Health, LLC dba Uqora. Additional information includes usage directions, warnings, inactive ingredients, and contact details for the distributor.*

FDA Label Image

2 (Carton 24 Ct)

Uqora Maximum UTI Pain Relief 99.5 mg phenazopyridine hydrochloride tablets, oral dosage form, in a 24-tablet package. The label highlights max strength and fast-targeted relief for burning, urgency, pain, and discomfort associated with urinary tract pain. Distributed by Uqora, Bonafide Health, LLC, with usage instructions and warnings included in a Drug Facts panel visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.